Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Anal cancer
Stage/Subtype:  stage IIIB anal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-7 of 7 for your search:
Start Over
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Cisplatin and Fluorouracil Compared with Carboplatin and Paclitaxel in Treating Patients with Inoperable Locally Recurrent or Metastatic Anal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: EA2133, NCI-2015-00771, 13/LO/1463, 2013-001949-13, 3847, CCR 3847, InterAACT CCR 3847, NCT02051868, NCT02560298
Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: EA2165, NCI-2017-01347, NCT03233711
Ph 1 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: POLARIS2013-001, NCI-2017-00851, NCT02102022
High-Dose-Rate Brachytherapy and Chemotherapy in Treating Patients with Locally Recurrent or Residual Rectal or Anal Cancer Undergoing Non-operative Management
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-104, NCI-2014-01649, NCT02199236
Radiation Therapy, Fluorouracil, and Mitomycin in Treating Patients with Stage I-IIIB Anal Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-075, NCI-2013-01820, NCT01858025
Start Over